Cargando…

Promising Schiff bases in antiviral drug design and discovery

Emerging and re-emerging illnesses will probably present a new hazard of infectious diseases and have fostered the urge to research new antiviral agents. Most of the antiviral agents are analogs of nucleosides and only a few are non-nucleoside antiviral agents. There is quite a less percentage of ma...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaushik, Shikha, Paliwal, Sarvesh Kumar, Iyer, Malliga R., Patil, Vaishali M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10171175/
https://www.ncbi.nlm.nih.gov/pubmed/37305208
http://dx.doi.org/10.1007/s00044-023-03068-0
_version_ 1785039373425704960
author Kaushik, Shikha
Paliwal, Sarvesh Kumar
Iyer, Malliga R.
Patil, Vaishali M.
author_facet Kaushik, Shikha
Paliwal, Sarvesh Kumar
Iyer, Malliga R.
Patil, Vaishali M.
author_sort Kaushik, Shikha
collection PubMed
description Emerging and re-emerging illnesses will probably present a new hazard of infectious diseases and have fostered the urge to research new antiviral agents. Most of the antiviral agents are analogs of nucleosides and only a few are non-nucleoside antiviral agents. There is quite a less percentage of marketed/clinically approved non-nucleoside antiviral medications. Schiff bases are organic compounds that possess a well-demonstrated profile against cancer, viruses, fungus, and bacteria, as well as in the management of diabetes, chemotherapy-resistant cases, and malarial infections. Schiff bases resemble aldehydes or ketones with an imine/azomethine group instead of a carbonyl ring. Schiff bases have a broad application profile not only in therapeutics/medicine but also in industrial applications. Researchers have synthesized and screened various Schiff base analogs for their antiviral potential. Some of the important heterocyclic compounds like istatin, thiosemicarbazide, quinazoline, quinoyl acetohydrazide, etc. have been used to derive novel Schiff base analogs. Keeping in view the outbreak of viral pandemics and epidemics, this manuscript compiles a review of Schiff base analogs concerning their antiviral properties and structural-activity relationship analysis.
format Online
Article
Text
id pubmed-10171175
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-101711752023-05-11 Promising Schiff bases in antiviral drug design and discovery Kaushik, Shikha Paliwal, Sarvesh Kumar Iyer, Malliga R. Patil, Vaishali M. Med Chem Res Review Article Emerging and re-emerging illnesses will probably present a new hazard of infectious diseases and have fostered the urge to research new antiviral agents. Most of the antiviral agents are analogs of nucleosides and only a few are non-nucleoside antiviral agents. There is quite a less percentage of marketed/clinically approved non-nucleoside antiviral medications. Schiff bases are organic compounds that possess a well-demonstrated profile against cancer, viruses, fungus, and bacteria, as well as in the management of diabetes, chemotherapy-resistant cases, and malarial infections. Schiff bases resemble aldehydes or ketones with an imine/azomethine group instead of a carbonyl ring. Schiff bases have a broad application profile not only in therapeutics/medicine but also in industrial applications. Researchers have synthesized and screened various Schiff base analogs for their antiviral potential. Some of the important heterocyclic compounds like istatin, thiosemicarbazide, quinazoline, quinoyl acetohydrazide, etc. have been used to derive novel Schiff base analogs. Keeping in view the outbreak of viral pandemics and epidemics, this manuscript compiles a review of Schiff base analogs concerning their antiviral properties and structural-activity relationship analysis. Springer US 2023-05-10 2023 /pmc/articles/PMC10171175/ /pubmed/37305208 http://dx.doi.org/10.1007/s00044-023-03068-0 Text en © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Review Article
Kaushik, Shikha
Paliwal, Sarvesh Kumar
Iyer, Malliga R.
Patil, Vaishali M.
Promising Schiff bases in antiviral drug design and discovery
title Promising Schiff bases in antiviral drug design and discovery
title_full Promising Schiff bases in antiviral drug design and discovery
title_fullStr Promising Schiff bases in antiviral drug design and discovery
title_full_unstemmed Promising Schiff bases in antiviral drug design and discovery
title_short Promising Schiff bases in antiviral drug design and discovery
title_sort promising schiff bases in antiviral drug design and discovery
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10171175/
https://www.ncbi.nlm.nih.gov/pubmed/37305208
http://dx.doi.org/10.1007/s00044-023-03068-0
work_keys_str_mv AT kaushikshikha promisingschiffbasesinantiviraldrugdesignanddiscovery
AT paliwalsarveshkumar promisingschiffbasesinantiviraldrugdesignanddiscovery
AT iyermalligar promisingschiffbasesinantiviraldrugdesignanddiscovery
AT patilvaishalim promisingschiffbasesinantiviraldrugdesignanddiscovery